Why the study?
Does pentoxifylline or cilostazol improve blood and plasma viscosity, fibrinogen, and erythrocyte deformability in adults with moderate to severe claudication?
Does pentoxifylline or cilostazol improve blood and plasma viscosity, fibrinogen, and erythrocyte deformability in adults with moderate to severe claudication?
Long-term administration of pentoxifylline or cilostazol does not significantly affect ex vivo rheologic characteristics of blood in patients with intermittent claudication, suggesting their clinical benefits are mediated by other mechanisms.
No takes yet. Share an insight, caveat, or question.
Rheologic effects should not be invoked for pentoxifylline or cilostazol in claudication; challenges mechanistic assumptions and directs research to alternative pathways.
Dawson et al. (2002) studied this question.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: